AstraZeneca licensed exclusive global rights to MEDI2070 (later brazikumab), a Phase 2b anti-IL-23p19 antibody for Crohn's disease, to Allergan for $250M upfront plus up to $1.27B in milestones plus tiered royalties (~$1.52B total). AstraZeneca passed one-third of payments to Amgen (original co-developer). Allergan later returned rights to AstraZeneca in 2020 to satisfy regulators ahead of AbbVie merger.